Molecure Receives Positive IDMC Recommendation to Continue KITE Clinical Study Without Protocol Changes (OATD-01 Development Program)

WARSAW, Poland, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Molecure S.A. (WSE: MOC), a clinical-stage biotechnology company, has received a positive recommendation from the IDMC to continue the Phase II KITE clinical study without changes to the protocol. The study is evaluating the efficacy and safety of OATD-01, a first-in-class CHIT1 inhibitor, in patients with active pulmonary sarcoidosis.